Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Other share classesJSPRW
Q4 2022 vs. Q3 2022
How the institutions holding Jasper Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 23 | 23 | 0 |
| Shares | 20.3M | 20.2M | −90.5K (−0.4%) |
| Value | $15.7M | $9.57M | −$6.18M (−39.2%) |
New holders (3)
Institutions that held Jasper Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 34,366 | $16.3K | 0.00% |
| Millennium Management LLC | 29,671 | $14.0K | 0.00% |
| Bank of America Corp | 36 | $18 | 0.00% |
Sold out (3)
Institutions that held Jasper Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Sectoral Asset Management Inc | 400,000 | $316.0K |
| Royal Bank of Canada | 2,555 | $2.00K |
| Ionic Capital Management LLC | 100 | $0 |